Get started
Author

Christie Nie

OpenAlex ID: A5028503196
Birtamimab plus standard of care in light-chain amyloidosis: the phase 3 randomized placebo-controlled VITAL trial
2023 · Morie A. Gertz, Adam D. Cohen, et al. · Blood · 77
Birtamimab in patients with Mayo stage IV AL amyloidosis: Rationale for confirmatory affirm-AL phase 3 study.
2022 · Morie A. Gertz, Vaishali Sanchorawala, et al. · Journal of Clinical Oncology · 13
Survival Benefit of Birtamimab in Mayo Stage IV AL Amyloidosis in the Phase 3 VITAL Study Consistent after Adjustment for Key Baseline Variables
2022 · Morie A. Gertz, Yuying Jin, et al. · Blood · 2
P-299 Health-Related Quality of Life in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care: Results From the VITAL Trial
2024 · Anita D'Souza, Vaishali Sanchorawala, et al. · Clinical Lymphoma Myeloma & Leukemia
Health-Related Quality of Life (HRQoL) in Patients With Mayo Stage IV Light Chain (AL) Amyloidosis Treated With Birtamimab Plus Standard of Care (SoC): Results From the VITAL Trial PC43 (#346)
2024 · Anita D'Souza, Vaishali Sanchorawala, et al.
Phase I/III study to confirm bioequivalence and safe switching of proposed biosimilar denosumab in postmenopausal osteoporosis
2020 · Jean-Jacques Body, Christie Nie, et al. · Bone Reports
PDF
Works count: 6
Citation count: 92
H-index: 2
I10-index: 2
Year
Topic
Type